Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, Schutz FA, Heng DYC, Wang F, Mataveli F, Chang YL, van Kooten Losio M, Suarez C, Motzer RJ; COSMIC-313 Investigators. Choueiri TK, et al. Among authors: fein le. N Engl J Med. 2023 May 11;388(19):1767-1778. doi: 10.1056/NEJMoa2212851. N Engl J Med. 2023. PMID: 37163623 Free PMC article. Clinical Trial.
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Chirgwin J, et al. Breast Cancer Res Treat. 2012 Jan;131(1):295-306. doi: 10.1007/s10549-011-1741-6. Epub 2011 Sep 4. Breast Cancer Res Treat. 2012. PMID: 21892704 Free PMC article. Clinical Trial.
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G. Kaufmann M, et al. Among authors: fein le. J Clin Oncol. 2000 Apr;18(7):1399-411. doi: 10.1200/JCO.2000.18.7.1399. J Clin Oncol. 2000. PMID: 10735887 Clinical Trial.
Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study.
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G. Kaufmann M, et al. Among authors: fein le. Clin Breast Cancer. 2000 Sep;1 Suppl 1:S15-8. doi: 10.3816/cbc.2000.s.003. Clin Breast Cancer. 2000. PMID: 11970744 Clinical Trial.
Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial.
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Cervek J, Fowst C, Polli A, Di Salle E, Massimini G, Piscitelli G. Kaufmann M, et al. Among authors: fein le. Eur J Cancer. 2000 Sep;36 Suppl 4:S86-7. doi: 10.1016/s0959-8049(00)00240-9. Eur J Cancer. 2000. PMID: 11056333 Clinical Trial.
Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
Ezcurdia L, Jovtis SL, Mickiewicz E, Temperley G, Rondinón M, Blajman C, Cóppola FS, Lewi D, Cazap E, Breier S, Fasce H, Fein L, Polera J, Triguboff E, Uranga G, Pasccón G, Luchina AM, Martínez CA, Politi PM, Rubio G, Alvarez AM. Ezcurdia L, et al. Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-53-S15-56. Semin Oncol. 1997. PMID: 9346223 Clinical Trial.
63 results